FBLG insider transaction filings
FibroBiologics, Inc. — 37 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-15. Screen FBLG transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 1 Form 4 filing. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 2.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Khoja Hamid — Chief Scientific Officer | 1 | — | — | 2 |
Recent Form 4 filings — FibroBiologics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-15 | 4 | Khoja Hamid — Chief Scientific Officer | Grant/award (A): 298,508 @ $1.68 · Grant/award (A): 298,508 (derivative) | EDGAR |
| 2026-06-23 | 4 | Cilento Richard C. Jr. — Director | Grant/award (A): 30,803 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Niklas Victoria Ninon Olivia — Director | Grant/award (A): 30,803 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Link Matthew — Director | Grant/award (A): 30,803 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Hoffman Robert E. — Director | Grant/award (A): 30,803 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Khoja Hamid — Chief Scientific Officer | Grant/award (A): 61,607 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | GARCIA RUBEN A — General Counsel | Grant/award (A): 61,607 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | O'HEERON PETE — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 92,410 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Davis Jason — Chief Financial Officer | Grant/award (A): 61,607 (derivative) @ $0 | EDGAR |
| 2026-03-05 | 4 | Khoja Hamid — Chief Scientific Officer | Purchase (P): 30,000 @ $0.38 | EDGAR |
| 2026-03-04 | 4 | O'HEERON PETE — CHIEF EXECUTIVE OFFICER, Director | Purchase (P): 17,428 @ $0.35 · Purchase (P): 18,200 @ $0.41 · Purchase (P): 15,872 @ $0.38 | EDGAR |
| 2026-03-03 | 4 | Davis Jason — Chief Financial Officer | Purchase (P): 70,000 @ $0.41 | EDGAR |
| 2026-03-02 | 4 | GARCIA RUBEN A — General Counsel | Purchase (P): 40,000 @ $0.33 | EDGAR |
| 2025-12-12 | 4 | GARCIA RUBEN A — General Counsel | Purchase (P): 140,000 @ $0.34 | EDGAR |
| 2025-06-12 | 4 | Niklas Victoria Ninon Olivia — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Cilento Richard C. Jr. — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Coen Stacy Ann — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Link Matthew — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Hoffman Robert E. — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | Davis Jason — Chief Financial Officer | Grant/award (A): 450,000 (derivative) @ $0 | EDGAR |
| 2025-05-27 | 4 | Khoja Hamid — Chief Scientific Officer | Purchase (P): 20,000 @ $0.84 | EDGAR |
| 2025-03-28 | 4 | GARCIA RUBEN A — General Counsel | Grant/award (A): 189,000 (derivative) @ $0 | EDGAR |
| 2025-03-28 | 4 | Khoja Hamid — CHIEF SCIENTIFIC OFFICER | Grant/award (A): 189,000 (derivative) @ $0 | EDGAR |
| 2025-03-28 | 4 | O'HEERON PETE — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 453,000 (derivative) @ $0 | EDGAR |
| 2024-12-30 | 4 | Khoja Hamid — CHIEF SCIENTIFIC OFFICER | Grant/award (A): 176,200 (derivative) @ $0 | EDGAR |
| 2024-12-30 | 4 | GARCIA RUBEN A — General Counsel | Grant/award (A): 176,200 (derivative) @ $0 | EDGAR |
| 2024-12-30 | 4 | O'HEERON PETE — Chief Executive Officer, Director | Grant/award (A): 406,339 (derivative) @ $0 | EDGAR |
| 2024-12-09 | 4 | O'HEERON PETE — Chief Executive Officer, Director | Gift (G): 100,000 @ $0 | EDGAR |
| 2024-12-05 | 4 | O'HEERON PETE — Chief Executive Officer, Director | Gift (G): 50,000 @ $0 | EDGAR |
| 2024-08-27 | 4 | Niklas Victoria Ninon Olivia — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2024-08-27 | 4 | Cilento Richard C. Jr. — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2024-08-27 | 4 | Coen Stacy Ann — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2024-08-27 | 4 | Link Matthew — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2024-08-27 | 4 | Hoffman Robert E. — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2024-08-12 | 4 | Khoja Hamid — Chief Scientific Officer | Purchase (P): 10,000 @ $1.90 | EDGAR |
| 2024-08-12 | 4 | O'HEERON PETE — Chief Executive Officer, Director | Purchase (P): 8,500 @ $1.91 | EDGAR |
| 2024-03-08 | 4 | GARCIA RUBEN A — General Counsel | Grant/award (A): 180,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — FibroBiologics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-18 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-15 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-24 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-24 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-07-09 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-29 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-23 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-05-01 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=FBLG returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →